Company: Eli Lilly
Tags: quota, territory
I have never in 12 years of pharma had the problem I have now: more demand than I can support. Mounjaro and Zepbound scripts are outpacing my capacity to service accounts properly. PCPs are calling me. I am not calling them. It is a bizarre problem to have. The flip side is that quota was set assuming this growth curve continues indefinitely, which it won't. I can already see the plateauing in my mature accounts. Once the growth flattens, quota won't adjust fast enough. I'm enjoying the ride but I'm not foolish enough to think this lasts. Saving aggressively and watching the horizon.
41 upvotes · 0 comments